3.2.2. General Mood/Depression

Participants reported an improved overall mood associated with the treatment at the 3-month follow-up (Figure 2C, N = 339; T = 15.3; *p* < 0.001), which was maintained up to 6 months (Figure 3C, N = 136; X<sup>2</sup> = 94.0; *p* < 0.001) as indicated by a significant reduction in the PHQ-9 questionnaire scoring. As shown in Table 2, the observed effect was strongly influenced by participants diagnosed with anxiety-related disorders, who reported slightly poorer baseline levels of mood/depression (13.72 vs. 12.78) and a significantly larger average improvement (7.14 vs. 3.36; T= −5.18; *p* < 0.01) in the PHQ-9 scale compared to those participants diagnosed with chronic pain after 3 months.
